[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. O'Rielly DD, Rahman P: Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies. Pharmgenomics Pers Med; 2010;3:15-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies.
  • Rheumatoid arthritis (RA) is a chronic heterogeneous autoimmune disorder of unknown etiology resulting in inflammation in the synovium, cartilage, and bone.
  • Genetic factors are also important in RA pharmacotherapy due to the gene-dependent activity of enzymes involved in the pharmacokinetics and/or pharmacodynamics of RA medications.
  • Indeed, there is great variability in drug efficacy as well as adverse events associated with any anti-rheumatic therapy and genetics is thought to contribute significantly to this inter-individual variability in response.
  • We will also review the therapeutic agents that are currently being utilized or presently being evaluated in the treatment of RA, along with potential pharmacogenetic markers that have been proposed for such medications.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1978 Apr 20;298(16):869-71 [147420.001]
  • [Cites] Rheum Dis Clin North Am. 1992 Nov;18(4):741-59 [1280845.001]
  • [Cites] Aust N Z J Med. 1991 Dec;21(6):844-9 [1818543.001]
  • [Cites] Arthritis Rheum. 1987 Nov;30(11):1205-13 [2446635.001]
  • [Cites] Clin Genet. 1989 Sep;36(3):178-82 [2676268.001]
  • [Cites] Ann Intern Med. 1989 Oct 15;111(8):641-9 [2802419.001]
  • [Cites] Cell. 1986 Aug 29;46(5):705-16 [3091258.001]
  • [Cites] Am J Hum Genet. 1988 Oct;43(4):414-21 [3177384.001]
  • [Cites] Am J Hum Genet. 1980 Sep;32(5):651-62 [7191632.001]
  • [Cites] Nat Genet. 1995 May;10(1):111-3 [7647779.001]
  • [Cites] J Rheumatol. 1995 Jun;22(6):1032-6 [7674226.001]
  • [Cites] J Clin Invest. 1993 Sep;92(3):1387-93 [7690781.001]
  • [Cites] Pharmacogenetics. 1994 Feb;4(1):39-42 [8004131.001]
  • [Cites] Am J Gastroenterol. 1993 Aug;88(8):1198-205 [8338087.001]
  • [Cites] Gut. 1995 Nov;37(5):674-8 [8549944.001]
  • [Cites] J Immunol. 1996 Mar 1;156(5):1937-41 [8596047.001]
  • [Cites] J Inherit Metab Dis. 1996;19(5):589-94 [8892013.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):608-14 [9103127.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1044-51 [9545395.001]
  • [Cites] Clin Exp Immunol. 1998 Sep;113(3):401-6 [9737669.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2856-62 [9763570.001]
  • [Cites] Crit Rev Immunol. 1998;18(5):389-418 [9784967.001]
  • [Cites] Ann Intern Med. 1998 Nov 1;129(9):716-8 [9841604.001]
  • [Cites] Arthritis Rheum. 1998 Dec;41(12):2196-204 [9870876.001]
  • [Cites] Arthritis Rheum. 1999 Jun;42(6):1071-9 [10366098.001]
  • [Cites] Scand J Gastroenterol Suppl. 1999;230:111-5 [10499471.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2001-8 [10580024.001]
  • [Cites] Arthritis Rheum. 2000 Jan;43(1):30-7 [10643697.001]
  • [Cites] Leukemia. 2000 Apr;14(4):567-72 [10764140.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001158 [10796420.001]
  • [Cites] J Immunol. 2001 Mar 15;166(6):4177-84 [11238669.001]
  • [Cites] Gut. 2001 May;48(5):591-2 [11302950.001]
  • [Cites] Eur J Clin Pharmacol. 2001 Apr;57(1):51-4 [11372592.001]
  • [Cites] Lancet. 2001 Sep 15;358(9285):903-11 [11567728.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Nov;15(11):1699-708 [11683683.001]
  • [Cites] Arthritis Rheum. 2001 Nov;44(11):2525-30 [11710708.001]
  • [Cites] Exp Hematol. 2002 Mar;30(3):237-44 [11882361.001]
  • [Cites] Rheumatology (Oxford). 2002 Feb;41(2):180-3 [11886967.001]
  • [Cites] Gut. 2002 Apr;50(4):485-9 [11889067.001]
  • [Cites] Hum Immunol. 2002 Jan;63(1):76-81 [11916172.001]
  • [Cites] Pharmacogenetics. 2002 Apr;12(3):183-90 [11927833.001]
  • [Cites] Arthritis Rheum. 2002 Apr;46(4):921-8 [11953968.001]
  • [Cites] Semin Arthritis Rheum. 2002 Jun;31(6):355-60 [12077707.001]
  • [Cites] Pharmacogenetics. 2002 Aug;12(6):429-36 [12172211.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12281-6 [12213961.001]
  • [Cites] J Immunol. 2002 Oct 15;169(8):4388-98 [12370372.001]
  • [Cites] Ann Rheum Dis. 2003 Jan;62(1):4-9 [12480661.001]
  • [Cites] Int J Mol Med. 2003 May;11(5):593-600 [12684695.001]
  • [Cites] Arthritis Rheum. 2003 May;48(5):1398-407 [12746913.001]
  • [Cites] Ann Rheum Dis. 2003 Jun;62(6):526-9 [12759288.001]
  • [Cites] Nat Genet. 2003 Aug;34(4):395-402 [12833157.001]
  • [Cites] Rheumatology (Oxford). 2004 Feb;43(2):156-63 [12923290.001]
  • [Cites] Clin Rheumatol. 2003 Sep;22(3):221-4 [14505215.001]
  • [Cites] Drug Saf. 2003;26(13):983-9 [14583072.001]
  • [Cites] Genes Immun. 2004 May;5(3):151-7 [14749714.001]
  • [Cites] Arthritis Rheum. 2004 Feb;50(2):400-12 [14872482.001]
  • [Cites] Pharm Res. 2004 Feb;21(2):324-9 [15032315.001]
  • [Cites] Arthritis Res Ther. 2004;6(2):R142-50 [15059278.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2167-79 [15152062.001]
  • [Cites] Am J Hum Genet. 2004 Aug;75(2):330-7 [15208781.001]
  • [Cites] Ther Drug Monit. 2004 Apr;26(2):186-91 [15228163.001]
  • [Cites] Arthritis Rheum. 2004 Jul;50(7):2113-21 [15248208.001]
  • [Cites] Nat Immunol. 2004 Oct;5(10):1052-60 [15334086.001]
  • [Cites] Ann Rheum Dis. 2005 Apr;64(4):575-81 [15345504.001]
  • [Cites] Ann Rheum Dis. 2004 Oct;63(10):1227-31 [15361376.001]
  • [Cites] Arthritis Rheum. 2004 Sep;50(9):2750-6 [15457442.001]
  • [Cites] Arthritis Rheum. 2004 Sep;50(9):2766-74 [15457444.001]
  • [Cites] Arthritis Rheum. 2004 Oct;50(10):3093-103 [15476205.001]
  • [Cites] Int J Clin Pharmacol Ther. 2004 Sep;42(9):496-503 [15487808.001]
  • [Cites] Immunol Rev. 2004 Dec;202:139-56 [15546391.001]
  • [Cites] Pharmacogenetics. 2004 Nov;14(11):733-9 [15564880.001]
  • [Cites] Arthritis Rheum. 2005 Jan;52(1):219-24 [15641066.001]
  • [Cites] Rheumatology (Oxford). 2005 Mar;44(3):280-6 [15657072.001]
  • [Cites] Ann Rheum Dis. 2005 Aug;64(8):1180-5 [15677700.001]
  • [Cites] Rheumatology (Oxford). 2005 Apr;44(4):547-52 [15695296.001]
  • [Cites] Rheumatology (Oxford). 2005 Jul;44(7):869-72 [15814578.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1063-8 [15818663.001]
  • [Cites] Arthritis Res Ther. 2005;7 Suppl 2:S4-14 [15833146.001]
  • [Cites] Curr Opin Rheumatol. 2005 May;17(3):299-304 [15838240.001]
  • [Cites] Genes Immun. 2005 Sep;6(6):459-61 [15875058.001]
  • [Cites] Pharmacol Rev. 2005 Jun;57(2):163-72 [15914465.001]
  • [Cites] Genes Immun. 2005 Sep;6(6):467-71 [15931231.001]
  • [Cites] Arthritis Rheum. 2005 Jun;52(6):1694-9 [15934099.001]
  • [Cites] Intern Med J. 2005 Jul;35(7):419-26 [15958113.001]
  • [Cites] Rheumatology (Oxford). 2005 Oct;44(10):1263-6 [15998632.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1134-8 [16001646.001]
  • [Cites] Hum Genet. 2005 Oct;118(1):58-66 [16025348.001]
  • [Cites] Genes Immun. 2005 Dec;6(8):720-2 [16107870.001]
  • [Cites] Pediatr Nephrol. 2005 Nov;20(11):1566-71 [16133063.001]
  • [Cites] J Rheumatol. 2005 Sep;32(9):1650-3 [16142855.001]
  • [Cites] Rheumatol Int. 2006 Jun;26(8):726-31 [16220288.001]
  • [Cites] Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv2-14 [16239380.001]
  • [Cites] Exp Mol Pathol. 2006 Apr;80(2):141-6 [16248997.001]
  • [Cites] Arthritis Rheum. 2005 Nov;52(11):3433-8 [16255021.001]
  • [Cites] Nat Genet. 2005 Dec;37(12):1317-9 [16273109.001]
  • [Cites] Arthritis Rheum. 2005 Dec;52(12):3813-8 [16320316.001]
  • [Cites] Am J Hum Genet. 2005 Dec;77(6):1044-60 [16380915.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):90-6 [16385500.001]
  • [Cites] Ann Rheum Dis. 2006 Sep;65(9):1213-8 [16439441.001]
  • [Cites] Arthritis Rheum. 2006 Feb;54(2):607-12 [16447238.001]
  • [Cites] Rheumatology (Oxford). 2006 Jul;45(7):804-7 [16449362.001]
  • [Cites] Arthritis Res Ther. 2006;8(2):R34 [16469113.001]
  • [Cites] Arthritis Rheum. 2006 Apr;54(4):1087-95 [16572443.001]
  • [Cites] Arthritis Rheum. 2006 Apr;54(4):1117-21 [16572446.001]
  • [Cites] Arthritis Res Ther. 2006;8(3):R75 [16635271.001]
  • [Cites] Arthritis Res Ther. 2006;8(3):R79 [16646982.001]
  • [Cites] Arthritis Res Ther. 2006;8(4):R105 [16817978.001]
  • [Cites] Can J Physiol Pharmacol. 2006 Jan;84(1):15-20 [16845886.001]
  • [Cites] Eur J Clin Pharmacol. 2006 Nov;62(11):933-7 [16932953.001]
  • [Cites] Biomed Pharmacother. 2006 Dec;60(10):678-87 [17071051.001]
  • [Cites] Rheumatol Int. 2007 Jul;27(9):827-33 [17265154.001]
  • [Cites] Scand J Rheumatol. 2006 Nov-Dec;35(6):435-40 [17343250.001]
  • [Cites] Nat Immunol. 2007 Apr;8(4):345-50 [17375096.001]
  • [Cites] J Immunol. 2007 Apr 15;178(8):4901-7 [17404271.001]
  • [Cites] Rheumatology (Oxford). 2007 Jun;46(6):1034-5 [17409133.001]
  • [Cites] Ann Rheum Dis. 2007 Nov;66(11):1525-30 [17456524.001]
  • [Cites] Pharmacogenet Genomics. 2007 Jun;17(6):383-90 [17502830.001]
  • [Cites] Nat Rev Immunol. 2007 Jun;7(6):429-42 [17525752.001]
  • [Cites] Ann Intern Med. 2007 Jun 5;146(11):797-808 [17548411.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):661-78 [17554300.001]
  • [Cites] Hepatogastroenterology. 2007 Apr-May;54(75):784-6 [17591062.001]
  • [Cites] Ann Rheum Dis. 2008 Mar;67(3):358-63 [17666451.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):465-71 [17681167.001]
  • [Cites] N Engl J Med. 2007 Sep 20;357(12):1199-209 [17804836.001]
  • [Cites] N Engl J Med. 2007 Sep 6;357(10):977-86 [17804842.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4704-10 [17878369.001]
  • [Cites] Nat Genet. 2007 Dec;39(12):1431-3 [17982455.001]
  • [Cites] Nat Genet. 2007 Dec;39(12):1477-82 [17982456.001]
  • [Cites] Clin Exp Rheumatol. 2007 Sep-Oct;25(5):775-81 [18078632.001]
  • [Cites] J Hum Genet. 2008;53(2):163-73 [18087673.001]
  • [Cites] J Korean Med Sci. 2007 Dec;22(6):973-80 [18162709.001]
  • [Cites] Ann Rheum Dis. 2008 Dec;67(12):1663-9 [18250114.001]
  • [Cites] Rheumatology (Oxford). 2008 Apr;47(4):399-402 [18263596.001]
  • [Cites] Arthritis Res Ther. 2008;10(1):R26 [18307784.001]
  • [Cites] Mol Med. 2008 May-Jun;14(5-6):293-300 [18309376.001]
  • [Cites] Rheumatol Int. 2008 Jul;28(9):901-8 [18309487.001]
  • [Cites] Arthritis Res Ther. 2008;10(2):205 [18394179.001]
  • [Cites] Arthritis Rheum. 2008 May;58(5):1211-5 [18438835.001]
  • [Cites] Arthritis Rheum. 2008 May;58(5):1275-83 [18438843.001]
  • [Cites] Arthritis Res Ther. 2008;10(3):R52 [18462498.001]
  • [Cites] Eur J Clin Pharmacol. 2008 Sep;64(9):871-6 [18496682.001]
  • [Cites] Arthritis Rheum. 2008 Jul;58(7):1974-80 [18576336.001]
  • [Cites] Eur J Clin Pharmacol. 2008 Nov;64(11):1057-68 [18607581.001]
  • [Cites] Hum Immunol. 2008 Sep;69(9):567-71 [18625278.001]
  • [Cites] Ann Rheum Dis. 2009 Jun;68(6):898-903 [18633125.001]
  • [Cites] Curr Drug Metab. 2008 Jul;9(6):532-7 [18680473.001]
  • [Cites] Hum Mol Genet. 2008 Nov 15;17(22):3532-8 [18713756.001]
  • [Cites] Arthritis Rheum. 2008 Sep;58(9):2598-602 [18759272.001]
  • [Cites] Ann Rheum Dis. 2009 Oct;68(10):1547-52 [18930989.001]
  • [Cites] Annu Rev Pathol. 2009;4:417-34 [18954286.001]
  • [Cites] Genes Immun. 2009 Mar;10(2):101-11 [18987647.001]
  • [Cites] Rheumatol Int. 2009 May;29(7):793-6 [19034456.001]
  • [Cites] Arthritis Rheum. 2009 Jan;60(1):30-8 [19116921.001]
  • [Cites] Pharmacogenomics. 2009 Feb;10(2):303-9 [19207032.001]
  • [Cites] J Rheumatol. 2009 Mar;36(3):539-45 [19208607.001]
  • [Cites] Arthritis Res Ther. 2009;11(2):R42 [19292917.001]
  • [Cites] Curr Opin Rheumatol. 2009 May;21(3):244-50 [19342956.001]
  • [Cites] Curr Opin Rheumatol. 2009 May;21(3):262-71 [19365266.001]
  • [Cites] Pharmacogenomics J. 2009 Jun;9(3):161-7 [19365401.001]
  • [Cites] Ann Rheum Dis. 2010 Mar;69(3):561-6 [19401279.001]
  • [Cites] Arthritis Rheum. 2009 May;60(5):1255-60 [19404967.001]
  • [Cites] Hum Mol Genet. 2009 Jul 15;18(14):2693-9 [19417005.001]
  • [Cites] Immunol Rev. 2009 May;229(1):307-21 [19426230.001]
  • [Cites] Pharmacol Rep. 2009 Mar-Apr;61(2):281-7 [19443940.001]
  • [Cites] Arthritis Res Ther. 2009;11(3):R70 [19445664.001]
  • [Cites] Ann Rheum Dis. 2010 Apr;69(4):666-70 [19470526.001]
  • [Cites] Mol Biol Rep. 2010 Jan;37(1):141-7 [19479340.001]
  • [Cites] Arthritis Res Ther. 2009;11(3):R99 [19563633.001]
  • [Cites] Arthritis Rheum. 2009 Sep;60(9):2577-84 [19714643.001]
  • [Cites] Nat Rev Rheumatol. 2009 Oct;5(10):531-41 [19798027.001]
  • [Cites] Cochrane Database Syst Rev. 2009;(4):CD007277 [19821401.001]
  • [Cites] Rheumatol Int. 2010 Mar;30(5):661-6 [19588142.001]
  • (PMID = 23226040.001).
  • [ISSN] 1178-7066
  • [Journal-full-title] Pharmacogenomics and personalized medicine
  • [ISO-abbreviation] Pharmgenomics Pers Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3513198
  • [Keywords] NOTNLM ; pharmacogenetics / rheumatoid arthritis / susceptibility genes
  •  go-up   go-down


2. Stewart M, Malkovska V, Krishnan J, Lessin L, Barth W: Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab. Ann Rheum Dis; 2001 Sep;60(9):892-3
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab.
  • A 55 year old man with chronic lymphocytic leukaemia (CLL) and rheumatoid arthritis (RA), treated for four years with methotrexate (MTX), who developed a B cell non-Hodgkin's lymphoma (B-NHL), is described.
  • After failure of radiation and chemotherapy, a complete remission was achieved with a combination of antibody treatment (rituximab) and EPOCH.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid / drug therapy. Lymphoma, B-Cell / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immunocompromised Host. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Male. Middle Aged. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / etiology. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11502618.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 4F4X42SYQ6 / Rituximab; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC1753822
  •  go-up   go-down


3. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, Reid JM, Goldenberg DM, Wegener WA, Carroll WL, Adamson PC, Children's Oncology Group Pilot Study: Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol; 2008 Aug 1;26(22):3756-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
  • PURPOSE: To determine the tolerability and serum concentration of epratuzumab, a humanized monoclonal antibody targeting CD22, administered alone and in combination with reinduction chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL), and to preliminarily assess tumor targeting and efficacy.
  • PATIENTS AND METHODS: Therapy consisted of a single-agent phase (epratuzumab 360 mg/m(2)/dose intravenously twice weekly x four doses), followed by four weekly doses of epratuzumab in combination with standard reinduction chemotherapy.
  • Two dose-limiting toxicities occurred: one grade 4 seizure of unclear etiology and one asymptomatic grade 3 ALT elevation.
  • In all but one patient, surface CD22 was not detected by flow cytometry on peripheral blood leukemic blasts within 24 hours of drug administration, indicating effective targeting of leukemic cells by epratuzumab.
  • CONCLUSION: Treatment with epratuzumab plus standard reinduction chemotherapy is feasible and acceptably tolerated in children with relapsed CD22-positive ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2003 Oct;17(10):1967-72 [14513046.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3971-8 [18711187.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5327-34 [15328168.001]
  • [Cites] J Clin Oncol. 1985 Jul;3(7):998-1004 [3860629.001]
  • [Cites] Blood. 1988 Oct;72(4):1286-92 [3167209.001]
  • [Cites] Blood. 1993 Feb 1;81(3):602-9 [8427957.001]
  • [Cites] Cancer Immunol Immunother. 1993 Oct;37(5):293-8 [7691407.001]
  • [Cites] Int J Cancer. 1994 Feb 15;56(4):538-45 [8112889.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3051-9 [12837807.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S [14506197.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):34-8 [7743235.001]
  • [Cites] Med Pediatr Oncol. 1996 Dec;27(6):505-14 [8888809.001]
  • [Cites] Annu Rev Immunol. 1997;15:481-504 [9143697.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4846-50 [15570088.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):368-76 [15599932.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5044-51 [15955901.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Arthritis Res Ther. 2006;8(3):R74 [16630358.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3880-6 [16864854.001]
  • [Cites] Mol Immunol. 2007 Feb;44(6):1331-41 [16814387.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Oct;6(10):1341-53 [17069520.001]
  • [Cites] Cancer. 2006 Dec 15;107(12):2826-32 [17099879.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5750-62 [17179109.001]
  • [Cites] Arthritis Res Ther. 2006;8(4):R129 [16859536.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3704-13 [17530024.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • (PMID = 18669463.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / CD22 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / epratuzumab
  • [Other-IDs] NLM/ PMC2654811
  •  go-up   go-down


Advertisement
4. Shah N, Zambidis ET: False-photosensitivity and transient hemiparesis following high-dose intravenous and intrathecal methotrexate for treatment of acute lymphoblastic leukemia. Pediatr Blood Cancer; 2009 Jul;53(1):103-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False-photosensitivity and transient hemiparesis following high-dose intravenous and intrathecal methotrexate for treatment of acute lymphoblastic leukemia.
  • We describe a patient who was treated with high-dose intravenous and intrathecal methotrexate for acute lymphoblastic leukemia, and who manifested a false photosensitivity reaction with no prior evidence of sun exposure.
  • The etiology of these events is obscure, but suggestive of a vasculitic or immune-mediated reaction to methotrexate.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • [Cites] Arch Argent Pediatr. 2008 Feb;106(1):42-6 [18636134.001]
  • [Cites] Cutis. 2000 Nov;66(5):379-82 [11107525.001]
  • [Cites] J Rheumatol. 1985 Apr;12(2):354-5 [4032407.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1845-50 [3465876.001]
  • [Cites] Cutis. 1987 Jan;39(1):49-51 [3802910.001]
  • [Cites] Neuropediatrics. 2008 Feb;39(1):46-50 [18504683.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2058-61 [2004323.001]
  • [Cites] J Am Acad Dermatol. 1999 May;40(5 Pt 1):702-7 [10321597.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Nov-Dec;25(10):1688-95 [15569732.001]
  • [Cites] Semin Arthritis Rheum. 2006 Jun;35(6):388-95 [16765716.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):178-84 [17947226.001]
  • [Cites] Clin Exp Pharmacol Physiol Suppl. 1979;5:57-61 [318498.001]
  • (PMID = 19326416.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL077595-01; United States / NHLBI NIH HHS / HL / HL077595-05; United States / NHLBI NIH HHS / HL / K08 HL077595-01; United States / NHLBI NIH HHS / HL / K08 HL077595-05; United States / NHLBI NIH HHS / HL / HL077595-04; United States / NHLBI NIH HHS / HL / K08 HL077595-02; United States / NHLBI NIH HHS / HL / HL077595-02; United States / NHLBI NIH HHS / HL / K08 HL077595-03; United States / NHLBI NIH HHS / HL / K08 HL077595-04; United States / NHLBI NIH HHS / HL / K08 HL077595; United States / NHLBI NIH HHS / HL / HL077595-03
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nucleic Acid Synthesis Inhibitors; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS129680; NLM/ PMC3073488
  •  go-up   go-down


5. Kong YC, Wei WZ, Tomer Y: Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann N Y Acad Sci; 2010 Jan;1183:222-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rapid advances in our understanding of the immune network have led to treatment modalities for malignancies and autoimmune diseases based on modulation of the immune response.
  • Yet therapeutic modulation has resulted in immune dysregulation and opportunistic autoimmune sequelae, despite prescreening efforts in clinical trials.
  • Uncategorized predisposing factors in these patients include major histocompatibility complex and gender genetics, prevalence of different autoimmune diseases, prior chemotherapy, underlying disorder (e.g., hepatitis C), and preconditioning regimens as part of organ and stem cell transplants.

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2008 Jul 12;372(9633):89-90 [18620932.001]
  • [Cites] Ann Rheum Dis. 2008 Sep;67(9):1322-7 [18055469.001]
  • [Cites] Autoimmun Rev. 2008 Sep;7(8):631-7 [18774118.001]
  • [Cites] Br J Dermatol. 2008 Sep;159(3):735-6 [18547306.001]
  • [Cites] Science. 2008 Oct 10;322(5899):271-5 [18845758.001]
  • [Cites] Clin Neurol Neurosurg. 2008 Nov;110(9):878-85 [18164542.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1786-801 [18946064.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1838-41 [18946071.001]
  • [Cites] Eur J Endocrinol. 1995 May;132(5):587-93 [7749499.001]
  • [Cites] Science. 1995 Nov 10;270(5238):985-8 [7481803.001]
  • [Cites] Immunity. 1995 Nov;3(5):541-7 [7584144.001]
  • [Cites] Toxicology. 1995 Dec 20;105(1):31-57 [8638283.001]
  • [Cites] Clin Exp Immunol. 1996 Sep;105(3):523-8 [8809144.001]
  • [Cites] J Hepatol. 1996 Jan;24(1):38-47 [8834023.001]
  • [Cites] J Hepatol. 1996 Sep;25(3):283-91 [8895006.001]
  • [Cites] Am J Med. 1996 Nov;101(5):482-7 [8948271.001]
  • [Cites] J Clin Invest. 1996 Dec 15;98(12):2819-26 [8981930.001]
  • [Cites] Clin Exp Immunol. 1997 Feb;107(2):359-63 [9030876.001]
  • [Cites] Clin Immunol Immunopathol. 1997 Sep;84(3):223-43 [9281381.001]
  • [Cites] Thyroid. 1997 Dec;7(6):891-6 [9459633.001]
  • [Cites] Ital J Gastroenterol Hepatol. 1998 Feb;30(1):71-6 [9615270.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12):2489-99 [9635566.001]
  • [Cites] QJM. 1998 Jun;91(6):393-9 [9709457.001]
  • [Cites] Oncologist. 2008;13 Suppl 4:16-25 [19001147.001]
  • [Cites] J Autoimmun. 2008 Nov;31(3):219-27 [18501558.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5 [19074257.001]
  • [Cites] J Immunol. 2009 May 1;182(9):5873-81 [19380836.001]
  • [Cites] J Autoimmun. 2009 Aug;33(1):68-76 [19375891.001]
  • [Cites] Autoimmun Rev. 2009 Sep;9(1):28-33 [19254781.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1167-72 [9064334.001]
  • [Cites] Lancet. 1999 Nov 13;354(9191):1691-5 [10568572.001]
  • [Cites] Immunol Today. 2000 Oct;21(10):484-9 [11071526.001]
  • [Cites] J Interferon Cytokine Res. 2000 Dec;20(12):1039-47 [11152569.001]
  • [Cites] Oncologist. 2001;6(1):34-55 [11161227.001]
  • [Cites] Neuro Endocrinol Lett. 2001;22(1):49-52 [11335880.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):1925-9 [11344186.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3525-32 [11502774.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):958-65 [11583749.001]
  • [Cites] Chin Med J (Engl). 1999 Jan;112(1):61-6 [11593644.001]
  • [Cites] Bone Marrow Transplant. 2001 Dec;28(12):1151-3 [11803358.001]
  • [Cites] J Intern Med. 2002 May;251(5):400-6 [11982739.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jun;56(6):793-8 [12072050.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2063-6 [12242445.001]
  • [Cites] J Intern Med. 2002 Oct;252(4):377-8; author reply 379 [12366611.001]
  • [Cites] J Clin Immunol. 2003 Jan;23(1):62-72 [12645861.001]
  • [Cites] J Immunol. 2003 Apr 1;170(7):3522-7 [12646613.001]
  • [Cites] Gastroenterology. 2003 May;124(6):1711-9 [12761728.001]
  • [Cites] Am J Transplant. 2006 May;6(5 Pt 1):1084-5 [16611348.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Jun;18(6):693-4 [16702862.001]
  • [Cites] Nature. 2003 May 29;423(6939):506-11 [12724780.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(1):89-95 [12815483.001]
  • [Cites] Thyroid. 2003 Jun;13(6):547-51 [12930598.001]
  • [Cites] Curr Opin Oncol. 2003 Nov;15(6):431-9 [14624225.001]
  • [Cites] Cell Immunol. 2003 Nov;226(1):20-9 [14746804.001]
  • [Cites] Clin Dev Immunol. 2003 Jun-Dec;10(2-4):161-5 [14768947.001]
  • [Cites] Leukemia. 2004 Mar;18(3):484-90 [14749699.001]
  • [Cites] Autoimmunity. 2003 Dec;36(8):511-8 [14984028.001]
  • [Cites] Clin Exp Med. 2004 Apr;3(4):199-210 [15103510.001]
  • [Cites] Endocrinology. 2004 Aug;145(8):3724-30 [15117875.001]
  • [Cites] Pathol Annu. 1978;13 Pt 2:399-413 [581904.001]
  • [Cites] Lancet. 1985 May 18;1(8438):1166 [2860373.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Nov;63(5):1086-90 [2944910.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Aug;24(8):1299-303 [2460358.001]
  • [Cites] Clin Exp Immunol. 1990 Jul;81(1):72-5 [2199098.001]
  • [Cites] Ann Hematol. 1991 Feb;62(1):25-31 [1903309.001]
  • [Cites] Ann Intern Med. 1991 Aug 1;115(3):178-83 [2058872.001]
  • [Cites] JAMA. 1991 Sep 11;266(10):1375-83 [1715409.001]
  • [Cites] Gastroenterology. 1992 Jun;102(6):2155-60 [1587439.001]
  • [Cites] Am J Med. 1992 Jun;92(6):693-7 [1605152.001]
  • [Cites] J Immunol. 1992 Aug 1;149(3):1086-92 [1634763.001]
  • [Cites] Am J Gastroenterol. 1994 Mar;89(3):399-403 [8122653.001]
  • [Cites] Haematologica. 1994 Jul-Aug;79(4):367-70 [7806093.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Mar;80(3):922-6 [7883851.001]
  • [Cites] Acta Haematol. 1995;93(1):31-5 [7725847.001]
  • [Cites] J Endocrinol Invest. 1998 Dec;21(11):748-52 [9972674.001]
  • [Cites] J Hepatol. 1999 May;30(5):794-800 [10365804.001]
  • [Cites] Eur J Endocrinol. 1999 Oct;141(4):325-31 [10526243.001]
  • [Cites] Am J Transplant. 2005 Mar;5(3):465-74 [15707400.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2499-506 [15728455.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):805-16 [15738052.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 2):874-86 [15760415.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):7433-9 [15905592.001]
  • [Cites] J Immunother. 2005 Jul-Aug;28(4):412-9 [16000961.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4133-7 [15811929.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4138-44 [15855253.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8471-8 [16166327.001]
  • [Cites] J Immunother. 2005 Nov-Dec;28(6):593-8 [16224277.001]
  • [Cites] J Immunol. 2005 Dec 1;175(11):7746-54 [16301685.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):1005-16 [16283570.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):8968-77 [16204013.001]
  • [Cites] Front Biosci. 2006;11:1234-43 [16368509.001]
  • [Cites] J Neurol. 2006 Jan;253(1):98-108 [16044212.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] Hepatology. 2006 Apr;43(4):661-72 [16557537.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2283-9 [16710025.001]
  • [Cites] Clin Immunol. 2006 Sep;120(3):247-59 [16797237.001]
  • [Cites] Clin Immunol. 2006 Oct;121(1):108-17 [16916620.001]
  • [Cites] Curr Opin Immunol. 2006 Dec;18(6):710-7 [17011768.001]
  • [Cites] J Clin Immunol. 2007 Jan;27(1):1-18 [17216565.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2643-548 [17119125.001]
  • [Cites] Haematologica. 2007 Apr;92(4):533-41 [17488664.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3644-53 [17530018.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):7020-7 [17638915.001]
  • [Cites] Oncologist. 2007 Jul;12(7):873-83 [17673618.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2562-6 [17680564.001]
  • [Cites] Endocrinol Metab Clin North Am. 2007 Dec;36(4):1051-66; x-xi [17983936.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8 [17982122.001]
  • [Cites] Autoimmun Rev. 2008 Jan;7(3):198-203 [18190878.001]
  • [Cites] J Autoimmun. 2008 May;30(3):116-20 [18242956.001]
  • [Cites] Arthritis Rheum. 2008 Feb;58(2):370-5 [18240243.001]
  • [Cites] J Clin Rheumatol. 2008 Jun;14(3):166-8 [18525437.001]
  • (PMID = 20146718.001).
  • [ISSN] 1749-6632
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK073681; United States / NCI NIH HHS / CA / CA125680; United States / NIDDK NIH HHS / DK / DK45960; United States / NIDDK NIH HHS / DK / R01 DK045960; United States / NCI NIH HHS / CA / R01 CA125680; United States / NIDDK NIH HHS / DK / DK61659; United States / NCI NIH HHS / CA / P30 CA022453; United States / NIDDK NIH HHS / DK / R01 DK061659; United States / NIDDK NIH HHS / DK / DK073681
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunologic Factors
  • [Number-of-references] 116
  • [Other-IDs] NLM/ NIHMS513225; NLM/ PMC3815555
  •  go-up   go-down


6. Singh YP, Agarwal V, Krishnani N, Misra R: Enthesitis-related arthritis in Kikuchi-Fujimoto disease. Mod Rheumatol; 2008;18(5):492-5
MedlinePlus Health Information. consumer health - Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enthesitis-related arthritis in Kikuchi-Fujimoto disease.
  • Articular manifestations in the form of arthralgias are common but frank arthritis is distinctly rare and dactylitis has not been reported yet.
  • Herein, we describe a young boy who presented with arthritis and dactylitis as the initial manifestation of KFD.
  • Two years earlier he presented with arthritis of the knee and ankle joints, which lasted for 12 months.
  • Work-up for infectious etiology, systemic lupus erythematosus and leukemia and lymphoma was negative.
  • Fever, lymphadenopathy and leukopenia dissipated with nonsteroidal anti inflammatory drug therapy, but the arthritis persisted.
  • A trial of methotrexate led to the resolution of the arthritis.

  • Genetic Alliance. consumer health - Kikuchi disease.
  • Genetic Alliance. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18470474.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Bowman SJ: Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol; 2002;31(5):251-9
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematological manifestations of rheumatoid arthritis.
  • OBJECTIVE: To inform clinical rheumatologists about the common and rarer hematological manifestations of rheumatoid arthritis with an emphasis on diagnosis and therapy and a particular reference to Felty's syndrome.
  • RESULTS: The hematological manifestations can be conveniently categorized into the broad areas of; anemia, particularly NSAID induced iron deficiency anemia and the anemia of chronic disease, neutropenia, particularly Felty's syndrome and the large granular lymphocyte syndrome and drug induced neutropenia; thrombocytopenia, particularly autoimmune and drug induced thrombocytopenia; and hematological malignancy.
  • Rarer conditions, their diagnosis and therapy are also described in this review.
  • CONCLUSION: Hematological manifestations of rheumatoid arthritis are very common.
  • A logical approach using easily available tests should allow straightforward decisions about diagnosis and therapy to be made, even in patients with some of the rarer manifestations.
  • [MeSH-major] Arthritis, Rheumatoid. Hematologic Diseases
  • [MeSH-minor] Anemia / etiology. Blood Platelet Disorders / etiology. Databases, Bibliographic. Felty Syndrome / blood. Felty Syndrome / complications. Felty Syndrome / diagnosis. Humans. Immunocompromised Host. Leukemia, Lymphoid / blood. Leukemia, Lymphoid / complications. Leukemia, Lymphoid / diagnosis. Lymphoma / etiology

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12455813.001).
  • [ISSN] 0300-9742
  • [Journal-full-title] Scandinavian journal of rheumatology
  • [ISO-abbreviation] Scand. J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 122
  •  go-up   go-down


8. Turgut B, Vural O, Demir M, Kaldir M: Candida arthritis in a patient with chronic myelogenous leukemia (CML) in blastic transformation, unresponsive to fluconazole, but treated effectively with liposomal amphotericin B. Ann Hematol; 2002 Sep;81(9):529-31
Hazardous Substances Data Bank. FLUCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candida arthritis in a patient with chronic myelogenous leukemia (CML) in blastic transformation, unresponsive to fluconazole, but treated effectively with liposomal amphotericin B.
  • Candida arthritis is quite rare and might be caused either by direct intra-articular inoculation of Candida or secondary to hematogeneous seeding of Candida in immunocompromised hosts.
  • Until now less than 50 cases of Candida arthritis have been reported in the literature.
  • We report a case of Candida arthritis, which occurred in a patient with chronic myelogenous leukemia (CML) in blastic transformation.
  • Aggressive chemotherapy and broad-spectrum antibiotics for a prolonged period for febrile neutropenia had been given to the patient.
  • Arthritis of the left knee appeared during the recovery phase of leukopenia.
  • Despite treatment with fluconazole, no clinical or microbiological improvement was obtained.
  • We can conclude that fluconazole might not be sufficient in some Candida arthritis cases and liposomal amphotericin B might be a good alternative in these resistant cases.
  • [MeSH-major] Amphotericin B / administration & dosage. Arthritis, Infectious / drug therapy. Candidiasis / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Phosphatidylcholines / administration & dosage. Phosphatidylglycerols / administration & dosage
  • [MeSH-minor] Blast Crisis. Drug Combinations. Drug Resistance. Fatal Outcome. Female. Fluconazole / administration & dosage. Humans. Middle Aged. Opportunistic Infections / drug therapy. Opportunistic Infections / etiology

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Infectious Arthritis.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12373355.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Phosphatidylcholines; 0 / Phosphatidylglycerols; 0 / liposomal amphotericin B; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole
  •  go-up   go-down


9. Naithani R, Rai S, Choudhry VP: Septic arthritis of hip in a neutropenic child caused by Salmonella typhi. J Pediatr Hematol Oncol; 2008 Feb;30(2):182-4
MedlinePlus Health Information. consumer health - Infectious Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Septic arthritis of hip in a neutropenic child caused by Salmonella typhi.
  • A 5-year-old male child was undergoing chemotherapy for pre-B acute lymphoblastic leukemia.
  • He developed Salmonella typhi arthritis of his left hip joint during neutropenic phase.
  • Infection was successfully treated with intravenous antibiotics without surgical management. S. typhi is a potential cause of arthritis, especially in immunocompromised children.
  • More than 100 other cases of Salmonella arthritis are reviewed and reveal a disease primarily of children and young adults with a favorable treatment response.
  • [MeSH-major] Arthritis, Infectious / etiology. Hip Joint. Neutropenia / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Typhoid Fever / complications

  • Genetic Alliance. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376276.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


10. Choi BR, Ahn MJ, Lee WS, Kim TH, Bae SC, Jun JB: Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy. Rheumatol Int; 2005 May;25(4):311-3
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy.
  • Acute leukemia is uncommonly seen with rheumatoid arthritis during or following treatment with low-dose methotrexate, a safe and effective treatment for the arthritic condition.
  • We describe here a 68-year-old woman with rheumatoid arthritis who developed acute erythroleukemia during low-dose methotrexate therapy (total dose 1702.5 mg).
  • [MeSH-major] Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid / complications. Arthritis, Rheumatoid / drug therapy. Leukemia, Erythroblastic, Acute / etiology. Methotrexate / therapeutic use
  • [MeSH-minor] Aged. Dose-Response Relationship, Drug. Drug Therapy, Combination. Female. Folic Acid / therapeutic use. Humans. Hydroxychloroquine / therapeutic use. Treatment Outcome


11. Balakrishnan C, Pathan E, Khodaiji S, Dasgupta A, Mangat G, Joshi VR: Myelodysplasia and acute myeloid leukaemia in a case of rheumatoid arthritis with secondary amyloidosis treated with chlorambucil. J Assoc Physicians India; 2004 May;52:423-5
Hazardous Substances Data Bank. CHLORAMBUCIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelodysplasia and acute myeloid leukaemia in a case of rheumatoid arthritis with secondary amyloidosis treated with chlorambucil.
  • Immunosuppressive therapy related secondary haematologic malignancy is well reported.
  • A 52 years lady with established rheumatoid arthritis developed reactive amyloidosis.
  • Ten months after stopping chlorambucil she developed pancytopenia and vitamin B12 deficient megaloblastic anaemia.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Arthritis, Rheumatoid / drug therapy. Chlorambucil / adverse effects. Leukemia, Myeloid / chemically induced. Myelodysplastic Syndromes / chemically induced
  • [MeSH-minor] Acute Disease. Amyloidosis / drug therapy. Amyloidosis / etiology. Fatal Outcome. Female. Humans. Kidney Diseases / drug therapy. Kidney Diseases / etiology. Middle Aged


12. Sakata N, Yasui M, Kawa K: Pneumococcal arthritis affects performance status in patients with chronic GVHD of the skin following allogeneic bone marrow transplantation. Int J Hematol; 2001 Jul;74(1):90-4
MedlinePlus Health Information. consumer health - Pneumococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pneumococcal arthritis affects performance status in patients with chronic GVHD of the skin following allogeneic bone marrow transplantation.
  • We encountered 2 patients with pneumococcal arthritis following bone marrow transplantation (BMT).
  • Twenty-four months after BMT and 7 months after the onset of EB-LPD, pneumococcal arthritis occurred in both knee joints.
  • The other patient, a 10-year-old girl, received multiagent immunosuppressive therapy for her chronic GVHD.
  • At 51 months following BMT, pneumococcal arthritis occurred in her left knee joint.
  • Chronic GVHD of the skin delayed the recovery from the arthritis in both patients.
  • Although vaccination against pneumococcus or preventive antibiotics should be administered to high-risk patients, early diagnosis and treatment may be the best strategy for pneumococcal arthritis.
  • [MeSH-major] Arthritis, Infectious / etiology. Bone Marrow Transplantation / adverse effects. Cross Infection / etiology. Graft vs Host Disease / etiology. Leukemia, Myelomonocytic, Acute / therapy. Pneumococcal Infections / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Skin / pathology
  • [MeSH-minor] Anti-Bacterial Agents. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Drug Therapy, Combination / therapeutic use. Epstein-Barr Virus Infections / etiology. Female. Humans. Immunocompromised Host. Knee Joint. Lymphoproliferative Disorders / etiology. Lymphoproliferative Disorders / virology. Male. Severity of Illness Index. Transplantation, Homologous / adverse effects

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Infectious Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1979 Dec;91(6):835-41 [42335.001]
  • [Cites] Bone Marrow Transplant. 1999 Apr;23(7):637-46 [10218839.001]
  • [Cites] Blood. 1981 Aug;58(2):360-8 [6454452.001]
  • [Cites] Bone Marrow Transplant. 1995 Jan;15(1):161 [7742752.001]
  • [Cites] Int J Hematol. 2000 Apr;71(3):278-82 [10846836.001]
  • [Cites] Bone Marrow Transplant. 1995 Apr;15(4):650 [7655398.001]
  • [Cites] J Nucl Med. 1983 Dec;24(12 ):1123-6 [6358431.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3683-6 [10845897.001]
  • [Cites] Bone Marrow Transplant. 1998 Feb;21(3):299-300 [9489655.001]
  • [Cites] Bone Marrow Transplant. 1990 Dec;6(6):371-83 [2129021.001]
  • [Cites] Support Care Cancer. 1993 Jul;1(4):195-9 [8193881.001]
  • [Cites] Bone Marrow Transplant. 1993 Aug;12(2):165-6 [8401365.001]
  • [Cites] Leuk Lymphoma. 1997 Jun;26(1-2):1-15 [9250782.001]
  • [Cites] Bone Marrow Transplant. 1995 Mar;15(3):455-60 [7599572.001]
  • [Cites] Bone Marrow Transplant. 1998 Jun;21(11):1137-43 [9645577.001]
  • (PMID = 11530813.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Number-of-references] 15
  •  go-up   go-down


13. Hamidou MA, Boumalassa A, Larroche C, El Kouri D, Bl├ętry O, Grolleau JY: Systemic medium-sized vessel vasculitis associated with chronic myelomonocytic leukemia. Semin Arthritis Rheum; 2001 Oct;31(2):119-26
MedlinePlus Health Information. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic medium-sized vessel vasculitis associated with chronic myelomonocytic leukemia.
  • OBJECTIVE: To determine the clinical aspects of systemic vasculitis associated with chronic myelomonocytic leukemia (CMML).
  • None had viral infection or drug-associated vasculitis.
  • All patients were treated with corticosteroids, and 7 received immunosuppressive drugs.
  • CONCLUSIONS: Systemic ANCA-negative polyarteritis nodosa-type vasculitis seems closely associated to CMML.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Vasculitis / etiology
  • [MeSH-minor] Aged. Aneurysm / diagnosis. Antibodies, Antineutrophil Cytoplasmic / blood. Drug Therapy, Combination. Enzyme-Linked Immunosorbent Assay. Fatal Outcome. Female. Fluorescent Antibody Technique, Indirect. Glucocorticoids / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Chronic Myelomonocytic Leukemia.
  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11590581.001).
  • [ISSN] 0049-0172
  • [Journal-full-title] Seminars in arthritis and rheumatism
  • [ISO-abbreviation] Semin. Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antineutrophil Cytoplasmic; 0 / Glucocorticoids; 0 / Immunosuppressive Agents
  •  go-up   go-down


14. Dennis G, Chitkara P: A case of human T lymphotropic virus type I-associated synovial swelling. Nat Clin Pract Rheumatol; 2007 Nov;3(11):675-80
MedlinePlus Health Information. consumer health - Infectious Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of human T lymphotropic virus type I-associated synovial swelling.
  • BACKGROUND: Human T lymphotropic virus type 1 (HTLV-I) is associated with T-cell activation, proliferation, and leukemogenesis.
  • HTLV-I is the causative agent of adult T cell leukemia/lymphoma and is associated with myelopathy/tropical spastic paraparesis, uveitis, polymyositis, synovitis, thyroiditis, and bronchoalveolar pneumonia.
  • Since T-cell abnormalities are present in those infected with HTLV-I, the clinical problems might result from abnormal immune function or from direct leukemic or lymphomatous cell infiltration of tissues in the body.
  • Consequently, obtaining synovial tissue for analyses is likely to be helpful in determining which process is causing the clinical symptoms.
  • INVESTIGATIONS: Physical examination, comprehensive metabolic panel, complete blood counts, urinalysis, serological testing for rheumatoid factor, antinuclear antibodies, hepatitis, and cytomegalovirus; western blot for HTLV-I/II, lymphocyte phenotyping of peripheral blood, polymerase chain reaction, plain radiographic imaging, CT, MRI skin biopsy with immunohistochemical analysis, lymph node biopsy with immunohistochemical analysis, lymphocyte phenotyping of synovial fluid, synovial tissue biopsy with immunohistochemical analysis of synovial tissue, and synovial tissue culture.
  • DIAGNOSIS: HTLV-I infected synovial cells in conjunction with leukemic/lymphomatous infiltration of synovial tissue.
  • MANAGEMENT: Chemotherapy protocol using alemtuzumab.
  • [MeSH-major] Arthritis, Infectious / etiology. Leukemia-Lymphoma, Adult T-Cell / complications. Synovitis / etiology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Humans. Male. Wrist Joint / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17968339.001).
  • [ISSN] 1745-8390
  • [Journal-full-title] Nature clinical practice. Rheumatology
  • [ISO-abbreviation] Nat Clin Pract Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


15. Almoallim H, Patterson AC: Microscopic polyangiitis sparing the kidneys in a long-term survivor after allogeneic bone marrow transplantation and graft-versus-host disease. Clin Rheumatol; 2005 Aug;24(4):439-41
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Graft vs Host Disease / etiology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Polyarteritis Nodosa / etiology
  • [MeSH-minor] Antibodies, Antineutrophil Cytoplasmic / analysis. Cyclophosphamide / therapeutic use. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Middle Aged. Prednisone / therapeutic use. Renal Circulation / physiology. Risk Assessment. Severity of Illness Index. Treatment Outcome


16. Starkebaum G: Chronic neutropenia associated with autoimmune disease. Semin Hematol; 2002 Apr;39(2):121-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic neutropenia with autoimmune diseases is associated mainly with rheumatoid arthritis (RA), as Felty's syndrome or large granular lymphocyte (LGL) leukemia, and with systemic lupus erythematosus (SLE).
  • Recent advances have allowed better understanding regarding the mechanism of neutropenia and improved options for treatment.
  • The role of soluble Fas-ligand (FasL) in inducing apoptosis of neutrophils has been clarified for LGL leukemia and increased neutrophil apoptosis has been described in neutropenic patients with SLE.
  • Treatments of neutropenia have included methotrexate, cyclosporine A, and granulocyte colony-stimulating factor (G-CSF) as well as granulocyte-macrophage colony-stimulating factor (GM-CSF).
  • [MeSH-minor] Antibodies, Antineutrophil Cytoplasmic / immunology. Chronic Disease. Humans. Neutropenia / drug therapy. Neutropenia / etiology. Neutropenia / immunology. Neutrophils / drug effects. Neutrophils / immunology. Neutrophils / pathology

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11957195.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antineutrophil Cytoplasmic
  • [Number-of-references] 58
  •  go-up   go-down


17. Biswas S, Keddington J, McClanathan J: Large B-cell lymphoma presenting as acute abdominal pain and spontaneous splenic rupture; a case report and review of relevant literature. World J Emerg Surg; 2006;1:35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Spontaneous rupture of the spleen is an uncommon dramatic abdominal emergency that requires immediate diagnosis and prompt surgical treatment to ensure the patients survival.
  • Acute leukemia and non Hodgkin lymphoma were the frequent causes followed by chronic myelogenous leukemia.
  • Male sex, adulthood, severe splenomegaly and cytoreductive chemotherapy were factors more often associated with splenic rupture.
  • Emergency splenectomy remains the cornerstone treatment for splenic rupture.
  • We present a case report of a "spontaneous splenic rupture" and discuss the presentation, etiology and treatment options along with discussion of relevant literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1996 May;83(5):632 [8689204.001]
  • [Cites] Pathology. 1994 Oct;26(4):493-6 [7892057.001]
  • [Cites] AJR Am J Roentgenol. 1995 Mar;164(3):631-5 [7863884.001]
  • [Cites] Cancer. 1981 Dec 15;48(12):2729-33 [7306928.001]
  • [Cites] Am J Clin Pathol. 1984 Jul;82(1):104-9 [6234792.001]
  • [Cites] Mich Med. 1966 Feb;65(2):105-10 [5901949.001]
  • [Cites] Arch Surg. 1972 May;104(5):652-7 [4503094.001]
  • [Cites] Am J Emerg Med. 1989 Jan;7(1):28-31 [2643958.001]
  • [Cites] Acta Haematol. 2005;113(4):255-7 [15983432.001]
  • [Cites] Am J Hematol. 2003 Oct;74(2):131-5 [14508801.001]
  • [Cites] Int Abstr Surg. 1958 Jan;106(1):1-11 [13495867.001]
  • [Cites] Lupus. 2001;10(12):876-8 [11787878.001]
  • [Cites] J Pediatr Surg. 1999 Mar;34(3):498-9 [10211667.001]
  • [Cites] Eur J Surg. 1999 Jul;165(7):712-3 [10452269.001]
  • [Cites] Ann Hematol. 2000 Mar;79(3):158-60 [10803939.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Feb;26(1):3-8 [11298158.001]
  • [Cites] Clin Infect Dis. 1993 Feb;16(2):223-32 [8443301.001]
  • [Cites] Radiographics. 1994 Mar;14(2):307-32 [8190956.001]
  • [Cites] Ann Hematol. 1996 Dec;73(6):297-302 [9003161.001]
  • [Cites] Clin Infect Dis. 1997 Aug;25(2):336-7 [9332543.001]
  • [Cites] Semin Arthritis Rheum. 1997 Dec;27(3):141-55 [9431585.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):276-8 [9934775.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jan-Feb;21(1):89-93 [9022775.001]
  • (PMID = 17129392.001).
  • [ISSN] 1749-7922
  • [Journal-full-title] World journal of emergency surgery : WJES
  • [ISO-abbreviation] World J Emerg Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1712221
  •  go-up   go-down


18. Asano Y, Bujor AM, Trojanowska M: The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. J Dermatol Sci; 2010 Sep;59(3):153-62
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systemic sclerosis (SSc) is an autoimmune inflammatory disease with unknown etiology characterized by microvascular injury and fibrosis of the skin and internal organs.
  • A growing body of evidence suggests that deficiency of the transcription factor Fli1 (Friend leukemia integration-1) has a pivotal role in the pathogenesis of SSc.
  • In this article, we review the impact of Fli1 deficiency on the pathogenesis of SSc and discuss a new therapeutic strategy for SSc by targeting the transcription factor Fli1.
  • [MeSH-major] Proto-Oncogene Protein c-fli-1 / metabolism. Scleroderma, Systemic / drug therapy. Scleroderma, Systemic / enzymology
  • [MeSH-minor] Acetylation / drug effects. Animals. Autoimmune Diseases / drug therapy. B-Lymphocytes / drug effects. Benzamides. Collagen Type I / antagonists & inhibitors. Down-Regulation. Drug Therapy, Combination. Epigenesis, Genetic. Extracellular Matrix / drug effects. Fibroblasts / drug effects. Gene Expression / drug effects. Hematopoiesis / drug effects. Humans. Imatinib Mesylate. Macrolides / pharmacology. Mice. Phosphorylation / drug effects. Piperazines / pharmacology. Piperazines / therapeutic use. Protein Kinase Inhibitors / pharmacology. Protein Kinase Inhibitors / therapeutic use. Protein Processing, Post-Translational / drug effects. Pyrimidines / pharmacology. Pyrimidines / therapeutic use. T-Lymphocytes / drug effects

  • Genetic Alliance. consumer health - Diffuse Scleroderma.
  • MedlinePlus Health Information. consumer health - Scleroderma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Gastroenterology. 2006 Oct;131(4):1235-52 [17030193.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):39870-80 [17074756.001]
  • [Cites] Oncogene. 2007 Jan 25;26(4):500-8 [16862174.001]
  • [Cites] Arthritis Rheum. 2007 Jan;56(1):311-22 [17195235.001]
  • [Cites] Arthritis Rheum. 2007 May;56(5):1694-705 [17469184.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):12-30 [17555444.001]
  • [Cites] Clin Biochem. 2007 Aug;40(12):837-42 [17493602.001]
  • [Cites] J Dermatol Sci. 2007 Sep;47(3):217-26 [17601707.001]
  • [Cites] Arthritis Rheum. 2007 Aug;56(8):2747-54 [17665441.001]
  • [Cites] Arthritis Res Ther. 2007;9 Suppl 2:S5 [17767743.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):34672-83 [17884818.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Dec 15;176(12):1243-50 [17717205.001]
  • [Cites] J Dermatol. 2008 Feb;35(2):63-9 [18271800.001]
  • [Cites] Rheum Dis Clin North Am. 2008 Feb;34(1):115-43; vii [18329536.001]
  • [Cites] Future Oncol. 2008 Apr;4(2):211-7 [18407734.001]
  • [Cites] Rheumatology (Oxford). 2008 May;47(5):735-7 [18326532.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Jul 1;178(1):81-8 [18420966.001]
  • [Cites] FASEB J. 2008 Jul;22(7):2214-22 [18326784.001]
  • [Cites] Rheumatology (Oxford). 2008 Aug;47(8):1239-43 [18559373.001]
  • [Cites] J Immunol. 2008 Aug 1;181(3):1644-54 [18641300.001]
  • [Cites] Arthritis Rheum. 2008 Aug;58(8):2528-37 [18668566.001]
  • [Cites] Arthritis Rheum. 2008 Aug;58(8):2549-52 [18668570.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):20839-48 [11278621.001]
  • [Cites] Leuk Res. 2001 Sep;25(9):821-5 [11489476.001]
  • [Cites] J Clin Invest. 2001 Nov;108(9):1395-403 [11696585.001]
  • [Cites] Biochim Biophys Acta. 2002 Oct 21;1592(2):123-7 [12379474.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):571-81 [12875977.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):253-64 [14722617.001]
  • [Cites] J Cell Biochem. 2004 Apr 1;91(5):896-903 [15034925.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1275-92 [15039216.001]
  • [Cites] Cancer. 2004 May 15;100(10):2064-78 [15139047.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):7123-35 [15153536.001]
  • [Cites] Genes Dev. 2004 Aug 1;18(15):1824-37 [15289456.001]
  • [Cites] Nucleic Acids Res. 2004;32(18):5693-702 [15498926.001]
  • [Cites] Arch Dermatol. 1972 Jan;105(1):59-66 [5009623.001]
  • [Cites] Arthritis Rheum. 2008 Aug;58(8):2543-8 [18668587.001]
  • [Cites] Clin Immunol. 2008 Oct;129(1):19-30 [18692443.001]
  • [Cites] Arch Dermatol. 2008 Sep;144(9):1106-9 [18794453.001]
  • [Cites] Rheumatology (Oxford). 2009 Jan;48(1):49-52 [18815156.001]
  • [Cites] Bone Marrow Transplant. 2008 Dec;42(11):757-60 [18762765.001]
  • [Cites] Mol Cell Biol. 2009 Jan;29(2):425-34 [19001092.001]
  • [Cites] Mol Cell Biol. 2009 Apr;29(7):1882-94 [19158279.001]
  • [Cites] Oncogene. 2009 Mar 12;28(10):1285-97 [19151753.001]
  • [Cites] Clin Res Cardiol. 2009 Apr;98(4):265-7 [19219392.001]
  • [Cites] Nat Rev Rheumatol. 2009 Apr;5(4):200-6 [19337284.001]
  • [Cites] Hematol Oncol Clin North Am. 2009 Oct;23(5):1043-63, vi [19825452.001]
  • [Cites] Recent Results Cancer Res. 2010;184:3-20 [20072827.001]
  • [Cites] Curr Opin Rheumatol. 2010 Mar;22(2):133-8 [20090527.001]
  • [Cites] Mayo Clin Proc. 2010 Feb;85(2):158-64 [20053713.001]
  • [Cites] Arthritis Rheum. 2010 Mar;62(3):878-89 [20131241.001]
  • [Cites] Am J Pathol. 2010 Apr;176(4):1983-98 [20228226.001]
  • [Cites] Curr Biol. 2008 Aug 26;18(16):1234-40 [18718762.001]
  • [Cites] Clin Rheumatol. 2000;19(2):165-6 [10791633.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5643-52 [10891501.001]
  • [Cites] Immunity. 2000 Aug;13(2):167-77 [10981960.001]
  • [Cites] Nucleic Acids Res. 2000 Nov 1;28(21):4291-8 [11058129.001]
  • [Cites] Arthritis Rheum. 2001 Feb;44(2):474-80 [11229480.001]
  • [Cites] J Clin Invest. 1974 Oct;54(4):880-9 [4430718.001]
  • [Cites] Arthritis Rheum. 1978 May;21(4):418-28 [350229.001]
  • [Cites] Genes Dev. 1991 Jun;5(6):908-18 [2044959.001]
  • [Cites] Nature. 1992 Sep 10;359(6391):162-5 [1522903.001]
  • [Cites] J Biol Chem. 1994 Jul 8;269(27):18216-22 [7517940.001]
  • [Cites] Am J Hum Genet. 1995 Mar;56(3):676-83 [7887422.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1805-14 [7703487.001]
  • [Cites] J Invest Dermatol. 1995 Aug;105(2):280-4 [7636314.001]
  • [Cites] Mol Cell Biol. 1995 Dec;15(12):6961-70 [8524263.001]
  • [Cites] Int J Cancer. 1995 Nov 15;63(4):500-4 [7591257.001]
  • [Cites] Genome Res. 1999 Jan;9(1):44-52 [9927483.001]
  • [Cites] J Cell Physiol. 1999 Oct;181(1):153-9 [10457363.001]
  • [Cites] J Clin Invest. 2004 Nov;114(9):1308-16 [15520863.001]
  • [Cites] Nature. 1964 May 16;202:708-9 [14190049.001]
  • [Cites] J Immunol. 2004 Nov 15;173(10):6481-9 [15528390.001]
  • [Cites] Blood. 2005 Jan 1;105(1):95-102 [15367440.001]
  • [Cites] FASEB J. 2005 Jan;19(1):1-11 [15629889.001]
  • [Cites] J Invest Dermatol. 2005 Feb;124(2):324-30 [15675950.001]
  • [Cites] Vitam Horm. 2005;70:69-103 [15727802.001]
  • [Cites] J Biochem. 2005 Mar;137(3):297-302 [15809330.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1237-47 [15818662.001]
  • [Cites] Exp Hematol. 2005 May;33(5):550-7 [15850832.001]
  • [Cites] Am J Pathol. 2005 May;166(5):1451-63 [15855645.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):886-92 [15854026.001]
  • [Cites] Rheumatology (Oxford). 2005 Jun;44(6):824-6 [15769789.001]
  • [Cites] Nucleic Acids Res. 2005;33(11):3540-9 [15972796.001]
  • [Cites] Arthritis Rheum. 2005 Sep;52(9):2897-905 [16142753.001]
  • [Cites] Circ Res. 2005 Sep 16;97(6):512-23 [16166562.001]
  • [Cites] N Engl J Med. 2005 Sep 29;353(13):1412-3 [16192491.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2811-21 [16200212.001]
  • [Cites] J Immunol. 2005 Dec 1;175(11):7708-18 [16301681.001]
  • [Cites] Rheumatology (Oxford). 2006 Feb;45(2):157-65 [16319104.001]
  • [Cites] Am J Pathol. 2006 Feb;168(2):499-510 [16436664.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 12;343(3):904-9 [16564026.001]
  • [Cites] FEBS Lett. 2006 May 15;580(11):2547-52 [16631755.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2531-41 [16775234.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2542-51 [16775235.001]
  • [Cites] J Invest Dermatol. 2006 Aug;126(8):1761-9 [16675963.001]
  • [Cites] Ann Intern Med. 2006 Jul 18;145(2):152-3 [16847299.001]
  • [Cites] Arthritis Rheum. 2006 Jul;54(7):2271-9 [16802366.001]
  • [Cites] J Biol Chem. 2006 Sep 1;281(35):25259-69 [16829517.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):717-8 [17001803.001]
  • (PMID = 20663647.001).
  • [ISSN] 1873-569X
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR042334
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benzamides; 0 / Collagen Type I; 0 / FLI1 protein, human; 0 / Macrolides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Protein c-fli-1; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ NIHMS525829; NLM/ PMC3826615
  •  go-up   go-down


19. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A: Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum; 2010 Aug;62(8):2517-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration.
  • METHODS: The FDA's Adverse Event Reporting System was searched to identify malignancies associated with the use of infliximab, etanercept, and adalimumab in children in whom therapy was initiated between the ages of 0 and 18 years.
  • The remaining reported cases involved a variety of different malignancies including leukemia, melanoma, and solid organ cancers.
  • The reporting rates for etanercept were elevated above background for lymphomas and were on par with background for all malignancies.
  • CONCLUSION: There is evidence that treatment with TNF blockers in children may increase the risk of malignancy.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Arthritis, Juvenile / therapy. Immunoglobulin G / adverse effects. Neoplasms / etiology
  • [MeSH-minor] Adalimumab. Adolescent. Antibodies, Monoclonal, Humanized. Child. Child, Preschool. Etanercept. Humans. Immunosuppressive Agents / adverse effects. Infant. Infliximab. Receptors, Tumor Necrosis Factor / therapeutic use. Risk. Treatment Outcome. United States. United States Food and Drug Administration

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Juvenile Arthritis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arthritis Rheum. 2010 Aug;62(8):2183-4 [20506203.001]
  • (PMID = 20506368.001).
  • [ISSN] 1529-0131
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 0 / Receptors, Tumor Necrosis Factor; B72HH48FLU / Infliximab; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept
  •  go-up   go-down


20. Fam AG, Dunne SM, Iazzetta J, Paton TW: Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum; 2001 Jan;44(1):231-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective evaluation of an oral desensitization regimen using gradual dosage-escalation of allopurinol in 32 patients (30 with gout and 2 with chronic lymphocytic leukemia) whose therapy was interrupted because of a pruritic cutaneous reaction to the drug.
  • Twenty-eight patients completed the desensitization procedure to a target allopurinol dosage of 50-100 mg/day, 21 without deviation from the protocol for a mean of 30.5 days (range 21-56 days) and 7 requiring dosage adjustments because of a recurrent rash over 53.8 days (range 40-189 days).
  • Seven of these 28 patients developed late cutaneous reactions 1-20 months postdesensitization, 4 responding to dosage modification and 3 discontinuing the drug.
  • CONCLUSION: The study confirms the long-term efficacy and safety of slow oral desensitization to allopurinol in patients with maculopapular eruptions, particularly in those with gout, who cannot be treated with uricosurics or other urate-lowering drugs.
  • [MeSH-major] Allopurinol / adverse effects. Allopurinol / immunology. Drug Eruptions / etiology

  • Hazardous Substances Data Bank. Allopurinol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11212165.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gout Suppressants; 63CZ7GJN5I / Allopurinol
  •  go-up   go-down


21. Kumana CR: Aspects of general medicine. Hong Kong Med J; 2008 Oct;14(5):385-90
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The chapters summarised include: Contemporary management of acute myocardial infarction; Imported infectious disease emergencies; New therapies in the management of type 2 diabetes; Stress and adrenal insufficiency; Making sense of a 'funny thyroid function test'; Myeloproliferative disorders: management and molecular pathogenesis; Drug allergies; Osteoporosis; Rheumatoid arthritis; Understanding migraine from bench to bedside.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18840910.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 2
  •  go-up   go-down


22. Hall RL, Leahy MF: Acquired Factor VIII autoantibody: four cases demonstrating the heterogenous nature of this condition and problems involved in diagnosis and treatment. Eur J Haematol; 2001 Mar;66(3):206-9
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired Factor VIII autoantibody: four cases demonstrating the heterogenous nature of this condition and problems involved in diagnosis and treatment.
  • The development of an autoantibody to human Factor VIII is rare and presents many problems for diagnosis and treatment.
  • A wide range of treatment modalities were used in these cases with no gold standard of treatment or widely accepted guidelines existing.
  • We describe four cases which demonstrate the heterogeneity of this condition and its treatment and review the recent literature on the subject.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arthritis, Rheumatoid / complications. Azathioprine / therapeutic use. Breast Neoplasms. Cardiovascular Agents / therapeutic use. Cardiovascular Diseases / complications. Cardiovascular Diseases / drug therapy. Chlorambucil / therapeutic use. Cyclophosphamide / therapeutic use. Female. Hematoma / etiology. Humans. Immunoglobulin G / immunology. Immunosuppressive Agents / therapeutic use. Infection / etiology. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Male. Neoplasms, Multiple Primary. Partial Thromboplastin Time. Prednisolone / therapeutic use. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Hemophilia.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11350490.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Cardiovascular Agents; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 18D0SL7309 / Chlorambucil; 8N3DW7272P / Cyclophosphamide; 9001-27-8 / Factor VIII; 9PHQ9Y1OLM / Prednisolone; MRK240IY2L / Azathioprine
  •  go-up   go-down


23. Borm GF, Lemmers O, Fransen J, Donders R: The evidence provided by a single trial is less reliable than its statistical analysis suggests. J Clin Epidemiol; 2009 Jul;62(7):711-715.e1
MedlinePlus Health Information. consumer health - Clinical Trials.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When it is difficult to predict or determine how trial-specific factors influence the results, the best way to evaluate the performance of a treatment is to use multiple, possibly smaller, trials.
  • [MeSH-minor] Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid / drug therapy. Data Interpretation, Statistical. Electromagnetic Fields / adverse effects. Humans. Leukemia, Radiation-Induced / epidemiology. Leukemia, Radiation-Induced / etiology. Outcome Assessment (Health Care) / methods. Patient Selection. Research Design

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Epidemiol. 2009 Aug;62(8):886-7; author reply 887-9 [19481419.001]
  • (PMID = 19171462.001).
  • [ISSN] 1878-5921
  • [Journal-full-title] Journal of clinical epidemiology
  • [ISO-abbreviation] J Clin Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  •  go-up   go-down


24. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ, Ball ED: CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood; 2009 Feb 12;113(7):1581-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Relapse of malignancy after allogeneic hematopoietic cell transplantation (allo-HCT) remains a therapeutic challenge.
  • Organ-specific immune adverse events (IAE) were seen in 4 patients (grade 3 arthritis, grade 2 hyperthyroidism, recurrent grade 4 pneumonitis).
  • Three patients with lymphoid malignancy developed objective disease responses following ipilimumab: complete remission (CR) in 2 patients with Hodgkin disease and partial remission (PR) in a patient with refractory mantle cell lymphoma.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Res. 1996;84:279-90 [8724634.001]
  • [Cites] J Immunol. 1999 Jun 1;162(11):6368-77 [10352249.001]
  • [Cites] Oncologist. 2007 Jul;12(7):864-72 [17673617.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):741-50 [15613700.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6043-53 [16087944.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):1005-16 [16283570.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2283-9 [16710025.001]
  • [Cites] Adv Immunol. 2006;90:297-339 [16730267.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):958-64 [17289891.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1810-5 [17363537.001]
  • [Cites] J Immunother. 2007 Nov-Dec;30(8):825-30 [18049334.001]
  • [Cites] Cancer Invest. 2007 Oct;25(7):613-31 [18027152.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8 [17982122.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2744-8 [17595333.001]
  • [Cites] Front Biosci. 2007;12:4568-94 [17485398.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1451-9 [17508005.001]
  • [Cites] Science. 1996 Mar 22;271(5256):1734-6 [8596936.001]
  • [Cites] Immunity. 1995 Nov;3(5):541-7 [7584144.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] Annu Rev Immunol. 2001;19:225-52 [11244036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10 [18287062.001]
  • [Cites] Cancer Immun. 2008;8:1 [18198818.001]
  • [Cites] J Exp Med. 1999 Aug 2;190(3):355-66 [10430624.001]
  • (PMID = 18974373.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00060372
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 9389-01A1
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / ipilimumab
  • [Other-IDs] NLM/ PMC2644086
  •  go-up   go-down


25. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP: Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford); 2010 Feb;49(2):271-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight patients were randomized to receive two cycles of RTX at baseline and 24 weeks [each cycle consisted of four weekly RTX infusions (375 mg/m(2))] in addition to standard treatment, whereas six patients (control group) received standard treatment alone.
  • [MeSH-major] Antibodies, Monoclonal, Murine-Derived / therapeutic use. Immunosuppressive Agents / therapeutic use. Scleroderma, Systemic / drug therapy
  • [MeSH-minor] Adult. Aged. B-Lymphocytes / drug effects. Biopsy. Cell Adhesion Molecules / metabolism. Collagen / metabolism. Drug Administration Schedule. Humans. Lung Diseases, Interstitial / drug therapy. Lung Diseases, Interstitial / etiology. Lung Diseases, Interstitial / physiopathology. Lymphocyte Depletion / methods. Middle Aged. Respiratory Function Tests / methods. Rituximab. Skin / immunology. Skin / metabolism. Skin / pathology. Tomography, X-Ray Computed. Vital Capacity / drug effects

  • Genetic Alliance. consumer health - Scleroderma.
  • MedlinePlus Health Information. consumer health - Scleroderma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 1991 Oct;18(10):1520-8 [1765976.001]
  • [Cites] Arch Intern Med. 1993 Jun 14;153(11):1337-42 [8507124.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):559-62 [9492775.001]
  • [Cites] Lancet. 1999 Jul 17;354(9174):220 [10421308.001]
  • [Cites] Arthritis Rheum. 2005 Feb;52(2):501-13 [15693003.001]
  • [Cites] J Rheumatol. 2005 May;32(5):832-40 [15868618.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4885-91 [15746077.001]
  • [Cites] Curr Opin Rheumatol. 2005 Nov;17(6):746-51 [16224253.001]
  • [Cites] Transplantation. 2006 Feb 27;81(4):573-82 [16495806.001]
  • [Cites] Leukemia. 2006 Jan;20(1):172-3 [16239908.001]
  • [Cites] Drugs. 2006;66(8):1041-57 [16789791.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2655-66 [16790698.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2667-76 [16790699.001]
  • [Cites] Blood. 2006 Jul 15;108(2):756-62 [16551963.001]
  • [Cites] Rheumatology (Oxford). 2006 Aug;45(8):1005-8 [16490756.001]
  • [Cites] Am J Pathol. 2006 Sep;169(3):954-66 [16936269.001]
  • [Cites] Rheumatology (Oxford). 2006 Dec;45(12):1572 [16998235.001]
  • [Cites] Ann Rheum Dis. 2003 Sep;62(9):904-5 [12922969.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12319-24 [14530402.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1721-33 [15188347.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1918-27 [15188368.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):641-50 [15277237.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2603-6 [15251978.001]
  • [Cites] Mol Immunol. 2004 Nov;41(12):1123-33 [15482848.001]
  • [Cites] Arthritis Rheum. 1980 May;23(5):581-90 [7378088.001]
  • [Cites] Nat Clin Pract Rheumatol. 2006 Dec;2(12):679-85 [17133253.001]
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3962-70 [17133610.001]
  • [Cites] Rheumatol Int. 2007 Feb;27(4):357-61 [17021713.001]
  • [Cites] Rheumatology (Oxford). 2007 Mar;46(3):442-5 [16899504.001]
  • [Cites] Clin Immunol. 2007 Apr;123(1):66-73 [17275413.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Jun;20(2):349-60 [17448966.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):623-4 [17454609.001]
  • [Cites] Ann Rheum Dis. 2007 Jul;66(7):966-9 [17234649.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1388-96 [17452515.001]
  • [Cites] Arthritis Rheum. 2007 Sep;56(9):3167-8 [17763433.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Nov 15;176(10):1026-34 [17717203.001]
  • [Cites] Nephrology (Carlton). 2007 Dec;12(6):553-8 [17995580.001]
  • [Cites] Rheumatology (Oxford). 2008 Apr;47(4):552-3 [18281368.001]
  • [Cites] Arthritis Rheum. 2009 Feb;60(2):578-83 [19180481.001]
  • [Cites] Ann Rheum Dis. 2010 Jan;69(1):193-7 [19103636.001]
  • [Cites] Arthritis Care Res. 1991 Mar;4(1):27-31 [11188583.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Dec;9(4):329-34 [11759059.001]
  • [CommentIn] Rheumatology (Oxford). 2010 Feb;49(2):201-2 [20032221.001]
  • (PMID = 19447770.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Cell Adhesion Molecules; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ PMC2806066
  •  go-up   go-down


26. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E: Rituximab for steroid-refractory chronic graft-versus-host disease. Blood; 2006 Jul 15;108(2):756-62
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We therefore designed a phase 1/2 study of anti-B-cell therapy with rituximab in steroid-refractory chronic GVHD.
  • Responses were limited to patients with cutaneous and musculoskeletal manifestations of chronic GVHD and were durable through 1 year after therapy.
  • The median dose of prednisone among treated subjects fell from 40 mg/day to 10 mg/day, 1 year after rituximab therapy (P < .001).
  • Antibody titers against Y chromosome-encoded minor HLA antigens fell and remained low, whereas titers against infectious antigens (EBV, tetanus) remained stable or rose during the treatment period.
  • We conclude that specific anti-B-cell therapy with rituximab may be beneficial for patients with steroidrefractory chronic GVHD.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Drug Resistance. Graft vs Host Disease / drug therapy. Steroids / pharmacology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. B-Lymphocytes / drug effects. B-Lymphocytes / pathology. Chronic Disease. Female. Humans. Male. Middle Aged. Musculoskeletal Diseases / drug therapy. Musculoskeletal Diseases / etiology. Prednisone / pharmacology. Rituximab. Salvage Therapy / methods. Skin Diseases / drug therapy. Skin Diseases / etiology

  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Jan 1;103(1):353-9 [14512314.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1502-5 [10666232.001]
  • [Cites] Ann Intern Med. 2000 Aug 15;133(4):275-9 [10929168.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3995-6 [11090092.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1196-201 [11222360.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(5):265-73 [11400948.001]
  • [Cites] Bone Marrow Transplant. 2001 Jul;28(2):121-9 [11509929.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3595-9 [11739162.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3868-70 [11739201.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2712-9 [11929757.001]
  • [Cites] Br J Haematol. 2002 Jun;117(3):771-3 [12028061.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(8):444-52 [12234170.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:113-6 [10707791.001]
  • [Cites] Leukemia. 2006 Jan;20(1):172-3 [16239908.001]
  • [Cites] Clin Immunol. 2005 Dec;117(3):207-13 [16169773.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3308-13 [16046530.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Jun;99(6):696-703 [15897856.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2973-8 [15613541.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3580-90 [15529346.001]
  • [Cites] Bone Marrow Transplant. 1998 Oct;22(8):735-41 [9827969.001]
  • [Cites] Blood. 2002 Jul 1;100(1):48-51 [12070007.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4364-9 [12036863.001]
  • [Cites] Haematologica. 2003 Mar;88(3):315-23 [12651271.001]
  • [Cites] J Hematother Stem Cell Res. 2003 Feb;12(1):9-10 [12662431.001]
  • [Cites] Bone Marrow Transplant. 2003 Jun;31(11):1023-5 [12774054.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):457-64 [12877674.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Aug;9(8):505-11 [12931119.001]
  • [Cites] Bone Marrow Transplant. 1999 Dec;24(11):1253-8 [10642818.001]
  • [Cites] Exp Hematol. 2004 Jan;32(1):28-35 [14725898.001]
  • [Cites] J Exp Med. 2004 Apr 19;199(8):1133-42 [15096539.001]
  • [Cites] Curr Opin Rheumatol. 2004 May;16(3):180-5 [15103242.001]
  • [Cites] Br J Haematol. 2004 May;125(4):435-54 [15142114.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2603-6 [15251978.001]
  • [Cites] Blood. 1996 Jan 15;87(2):818-26 [8555508.001]
  • [Cites] Bone Marrow Transplant. 1997 Jun;19(11):1129-36 [9193757.001]
  • (PMID = 16551963.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00136396
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL070149
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Steroids; 4F4X42SYQ6 / Rituximab; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ PMC1895490
  •  go-up   go-down


27. Kim HR, Hong JH, Yoon CH, Lee SH, Park SH, Kim HY: Arthritis preceding acute biphenotypic leukemia. Clin Rheumatol; 2006 May;25(3):380-1
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arthritis preceding acute biphenotypic leukemia.
  • [MeSH-major] Arthritis / etiology. Leukemia / complications
  • [MeSH-minor] Acute Disease. Adult. Ankle / pathology. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antineoplastic Agents / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Pain / drug therapy. Phenotype

  • Genetic Alliance. consumer health - Acute Biphenotypic Leukemia.
  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Haematol. 1999 Mar;101(1):1-6 [10085431.001]
  • [Cites] Wiad Lek. 1998;51 Suppl 4:296-9 [10731987.001]
  • [Cites] Semin Arthritis Rheum. 1994 Aug;24(1):48-56 [7985037.001]
  • (PMID = 16220224.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents
  •  go-up   go-down


28. Broussais F, Kawashima M, Marotte H, Miossec P: Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab. Ann Rheum Dis; 2005 Mar;64(3):509-10
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antirheumatic Agents / adverse effects. Arthritis, Rheumatoid / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / etiology. Tuberculosis, Pulmonary / etiology


29. Edwards SA, Cranfield T, Clarke HJ: Atypical presentation of septic arthritis in the immunosuppressed patient. Orthopedics; 2002 Oct;25(10):1089-90
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical presentation of septic arthritis in the immunosuppressed patient.
  • [MeSH-major] Arthritis, Infectious / diagnosis. Escherichia coli Infections / diagnosis. Hip Joint
  • [MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Diagnosis, Differential. Drainage / methods. Drug-Related Side Effects and Adverse Reactions. Humans. Leukemia, T-Cell / drug therapy. Male. Pancytopenia / etiology. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - E. Coli Infections.
  • MedlinePlus Health Information. consumer health - Infectious Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12401018.001).
  • [ISSN] 0147-7447
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down






Advertisement